Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 14/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.55 |
| ▸ | SRC | P12931 | 10/20 | 0.54 |
| ▸ | SYK | P43405 | 10/20 | 0.54 |
| ▸ | LCK | P06239 | 2/20 | 0.54 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6547720 | 1.00 | GSK3A (0.58) | GSK3AMAPK14SRCSYKLCK | |
| SCHEMBL6547812 | 1.00 | GSK3A (0.58) | GSK3AMAPK14SRCSYKLCK | |
| SCHEMBL6546837 | 0.89 | MAPK14 (0.61) | GSK3AMAPK14SRCSYKLCK | |
| SCHEMBL6549990 | 0.89 | GSK3A (0.67) | GSK3AMAPK14SRCSYKCXCL8 | |
| SCHEMBL6549337 | 0.89 | GSK3A (0.67) | GSK3AMAPK14SRCSYKCXCL8 | |
| SCHEMBL6300952 | 0.89 | GSK3A (0.67) | GSK3AMAPK14SRCSYKCXCL8 | |
| SCHEMBL6545708 | 0.88 | GSK3A (0.57) | GSK3AMAPK14SRCSYKLCK | |
| SCHEMBL6547744 | 0.87 | GSK3A (0.60) | GSK3AMAPK14SRCSYKLCK | |
| SCHEMBL6546894 | 0.87 | GSK3A (0.59) | GSK3AMAPK14SRCSYKLCK | |
| SCHEMBL6298566 | 0.86 | GSK3A (0.56) | GSK3AMAPK14SRCSYKLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381592-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-01-21 | — | — | EP | claimed |
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | BOEHRINGER INTELHEIM PHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | claimed |
| WO-2002083628-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | claimed |
| US-6765009-B2 | N-(5-TERT-BUTYL-3-(3-(4-((2-DIMETHYLAMINOMETHYL-PYRIDIN-4-YL) -PIPERAZIN-1-YL-METHYL) NAPHTHALEN-1-YL)UREIDO)-2-METHOXYPHENYL) METHANESULFONAMIDE FOR EXAMPLE; CYTOKINE INHIBITORS FOR TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | RELA, NFKBIA, NQO1 | GSK3A 3419/4885MAPK14 3841/4885SRC 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.